Welcome to the Juno Therapeutics, Inc. (“Juno”) Twitter feed. We would like to hear from you and will do our best to respond to you in a timely nature. Given healthcare and securities laws and regulations, our responses may be limited in nature. Questions or comments directly related to products or product candidates, clinical trials, financial matters, ongoing legal matters, or regulatory issues will not be addressed.
Please note that Juno cannot provide medical advice. Any questions regarding your condition, treatment or medical side effects should be directed to your physician, pharmacist, or other healthcare professional immediately.
Juno’s Twitter posts may include links to certain websites or other content (e.g., videos or graphics) that are not created or controlled by Juno. Juno cannot attest to the accuracy of information provided by such websites or included in such content. If Juno provides a link to such a website or content, this does not constitute an endorsement by Juno or any of its employees or agents of the information presented on the non-Juno website or in the non-Juno content. Also, external websites or content are not within the control of Juno Therapeutics or Twitter and may not follow the same privacy, security, or accessibility policies that are applicable to the Juno Twitter feed or Juno website. Once you visit the external website or content, you may be subject to the policies of that site.
Juno Therapeutics, Inc. Twitter posts may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, business plans, and development timelines. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno’s product development activities and clinical trials; Juno’s ability to obtain regulatory approval for and to commercialize its product candidates; Juno’s ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno’s competitors with respect to competing treatments and technologies; Juno’s dependence on third-party collaborators and other contractors in Juno’s research and development activities, including for the conduct of clinical trials and the manufacture of Juno’s product candidates; Juno’s dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno’s ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno’s business in general, see Juno’s most recently filed periodic report (Annual Report on 10-K or Quarterly Report on 10-Q) with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they were originally posted. Juno disclaims any obligation to update these forward-looking statements.